Novo Nordisk reported a rapid uptake of its oral Wegovy launch, with prescriptions rising roughly 500% in the product’s second week and prescriptions surpassing 18,000 in the same period. The company’s pill formulation of semaglutide has drawn immediate market demand following launch. Analysts flagged the quick ramp as evidence of robust patient and prescriber interest in oral GLP‑1 options. The faster-than-expected adoption could pressure supply chains, influence payer coverage debates, and intensify competition among obesity and diabetes drugmakers.